A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

Part of paid clinical trials in Austin, Texas.

Sponsor
Gilead Sciences
Study ID
NCT07703878
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GS-1206 — DRUG
    Administered Orally

Study Details

The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.

Key Dates

First listed
Jul 15, 2026
Start date
Jul 17, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
302 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: Dose Escalation
    Participants will receive escalating doses of GS-1206 monotherapy one time daily up to 35 cycles.
  • Experimental: Part B: Dose Expansion
    Participants will be enrolled in different indication specific cohorts. Participants will receive GS-1206 monotherapy at the recommended dose one time daily up to 35 cycles.

Primary Outcome Measure

Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs) [ Time Frame: First dose up to 21 days post first dose ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
NEXT Oncology DallasAustinTexas75039-
NEXT OncologySan AntonioTexas78229-
START San Antonio, LLCSan AntonioTexas78229-

Find similar trials in Austin, TX

By research site
NEXT Oncology Dallas· Austin, TXNEXT Oncology· San Antonio, TXSTART San Antonio, LLC· San Antonio, TX

Related Studies